Health Canada recommends stopping treatment with SGLT2 inhibitors at least three days before surgery or other invasive procedures requiring prolonged fasting.
While the shortage of Ozempic in the U.S. prompts patients and caregivers to turn to compounded products, the Food and Drug Administration is concerned about dosing errors causing overdoses.
For those at high risk of diabetes, a threshold of four years of maintaining non-diabetic status could reduce the risk of death and cardiovascular complications.
Cohort study finds lower hazards of all-cause mortality, adverse cardiovascular events, acute kidney injury and adverse kidney events with tirzepatide versus GLP-1 RAs.
